OBJECTIVES: Recent advances in neoadjuvant chemoradiotherapy (nCRT) have significantly increased the rates of pathological complete response achieved by patients with oesophageal cancer. Consequently, a watchful waiting strategy based on 'active endoscopic surveillance and surgery as needed' has been proposed for cases without clinical evidence of disease after neoadjuvant chemoradiotherapy. Here, we investigated whether endoscopic surveillance is a reliable tool for the detection of the initially unidentified residual cancer in this patient group.
INTRODUCTION
Neoadjuvant chemoradiotherapy (nCRT) is an effective first-line treatment option for patients with locally advanced oesophageal cancer [1, 2] . Recent advances in nCRT has led to significant improvements in the pathological complete response (pCR) rates observed in this patient group [3] . Because surgical specimens classified as having 'no residual cancer' are increasingly common, a policy based on 'close endoscopic surveillance and surgery as needed' has been recently advocated for patients without clinical evidence of disease [i.e. clinical complete response (cCR)] following nCRT [4, 5] . Theoretically, a watchful waiting strategy can potentially be useful in cCR patients for identifying those who have truly achieved pCR. However, it should be noted that cCR has a low specificity for pCR, as only 23-40% of cCR patients have actually obtained pCR (cCR/pCR) [6, 7] . Importantly, the question as to whether a close endoscopic surveillance can effectively identify the presence of residual cancer in cCR patients who failed to achieve pCR (cCR/no-pCR) remains open [6] [7] [8] . In this scenario, a detailed analysis of the distribution of residual cancer in cCR/no-pCR patients is essential before considering a 'surgery as needed' strategy. In this regard, it is expected that initially unidentified residual cancers can be diagnosed through periodic endoscopic surveillance when the mucosa layer is involved by cancer. In contrast, residual cancer not involving the mucosa could make detection by endoscopy more difficult. Shapiro et al. [9] have previously shown a high rate of mucosal involvement after nCRT. Although they suggested that most of the initially unidentified residual cancers can be successfully diagnosed through serial endoscopic examinations, their study population was heterogeneous in terms of response to nCRT. In general, patients with poor response to nCRT are characterized by grossly visible mucosal lesions that are unlikely to be missed on endoscopic biopsies made for surveillance purposes. Consequently, data from a cohort that includes patients who responded poorly to nCRT may overestimate the feasibility of a 'surgery as needed' approach [9] .
In the present study, we hypothesized that endoscopic surveillance might not be sufficient to detect initially unidentified residual cancers in patients with cCR to nCRT. To address this issue, we selected patients with oesophageal squamous cell carcinoma (ESCC) who were classified as having cCR to nCRT but who had evidence of residual cancer in their surgical specimens. The detailed anatomical locations of the initially unidentified residual cancers were determined through a careful pathological rereview of oesophageal specimens. The prevalence of residual cancer was analysed in relation to each anatomical layer of the oesophagus as well as lymph node stations.
METHODS

Patients
A retrospective review of the clinical records of patients with locally advanced ESCC who had undergone surgical resection following nCRT at the Chang Gung Memorial Hospital (Taiwan) between January 1997 and December 2014 was performed. Patients who were coded as having achieved cCR (ycT0N0M0) in the data set were initially selected. We then carefully re-reviewed all of the clinical data, which were jointly discussed by our oesophageal cancer multidisciplinary team using the cCR criteria listed below. Only patients who reached a consensus on the achievement of cCR were deemed eligible. Patients were staged according to the seventh edition (2010) of the American Joint Committee on Cancer (AJCC) staging criteria. Pretreatment staging was based on computed tomography (CT) of the chest and abdomen, oesophagography, endoscopic ultrasound (EUS) and positron emission tomography (PET, introduced as of 2007). Because the study was based on a retrospective review of clinical charts, the Institutional Review Board of the Chang Gung Memorial Hospital waived the need for informed consent (104-1742B).
Neoadjuvant chemoradiotherapy and restaging workup
In our institution, nCRT followed by surgery was performed in patients with locally advanced oesophageal cancer located in the non-cervical area (cT2-4aNany or T1N+, AJCC Seventh Edition Staging Manual) who were medically fit for surgery. Two nCRT regimens were utilized throughout the study period 
Definition of clinical complete response
The diagnosis of cCR was made according to both endoscopy and CT findings. Patients were deemed to have achieved cCR when both endoscopic and radiological complete responses were evident. All of the endoscopic evaluations were performed by 3 experienced gastroenterologists. Endoscopic CR was defined in keeping with the Japanese endoscopic criteria as follows: (i) disappearance of the tumour lesion, (ii) disappearance of ulceration (slough) and (iii) absence of cancer cells in biopsy specimens [10] . If any suspicious lesion was identified on upper endoscopy following nCRT, a minimum of 3 biopsy samples were acquired to determine whether tumour cells were present. In the absence of identifiable lesions on upper endoscopy, random biopsies were acquired from the previous tumour site. CR on CT imaging was defined according to the response evaluation criteria in solid tumours criteria [11] . When the aforementioned criteria were not both satisfied, the site was coded as 'no-cCR'. PET-CR was defined as a decrease in fluorodeoxyglucose uptake in the primary tumour area and the affected lymph nodes to a level that was indistinguishable from the surrounding normal tissue [12] . Diffuse fluorodeoxyglucose accumulation in the field of radiotherapy in the absence of focal activity was considered as radiation-induced oesophagitis and classified as PET-CR.
Surgical resection following neoadjuvant chemoradiotherapy
In the absence of contraindications, oesophagectomy was scheduled in all patients. Eligibility for the operation was based on the following criteria: (i) medical fitness for surgery, with an American Society of Anesthesiologist (ASA) score of 3 or less; (ii) absence of tracheo-oesophageal fistula and (iii) no evidence of metastases to solid organs and/or distant lymph nodes. The standard surgical approach consisted of a right-side transthoracic oesophagectomy with intrathoracic (Ivor-Lewis procedure) or neck anastomosis (Mackeown procedure). Two-field lymph node dissection was performed in all patients.
Pathological examination
Surgical specimens were opened longitudinally and then fixed overnight in a 10% formaldehyde solution. When residual tumours were present, a careful examination of representative sections was performed with the goal of determining the maximal depth of tumour invasion. In the absence of gross tumours, we sampled ulcerated or fibrotic areas that subsequently underwent a thorough examination. A careful re-review of all of the originally resected specimens was performed by 2 experienced pathologists (C.-J.Y. and W.-Y.C.). The pathological response to nCRT was graded according to the 3-point tumour regression grade (TRG) as follows: TRG1, 0% residual cancer; TRG2, 1-50% residual cancer; TRG3, >50% residual cancer [13, 14] .
Post-therapy surveillance
During the first 2 study years, the surveillance protocol consisted of chest X-ray (performed every 3 months) and CT scans (every 6 months). Endoscopy was performed for patients with recurrent symptoms of dysphagia. Follow-up data were obtained from medical records and the referring physicians. The Taiwanese National Cancer Registry was used to integrate missing follow-up information.
Statistical analysis
Descriptive statistics were used to summarize the study variables. Continuous data are expressed as means ± standard deviations, whereas skewed continuous data are expressed as their medians and interquartile ranges. Categorical variables were summarized as frequency counts and percentages. The Student's t-test was used to compare continuous variables, whereas the MannWhitney U-test was used to compare skewed continuous data. Categorical data were compared using the Pearson's v 2 test or the Fisher's exact test (when cells had expected counts of <5). Univariable logistic regression models were used to identify significant predictors of pCR in the cCR group. Because of the rare number of events for certain predictors, multivariable analysis was not performed. Results were expressed as odds ratios with their 95% confidence intervals. In the subgroup of patients who received PET before surgery, the McNemar's test and the kappa statistic were used to assess the concordance between PET findings and the final results of pathology. Overall survival (OS) rate was calculated from the date of surgery to the date of death (or censored at the date of the last follow-up, i.e. 31 May 2016).
Survival curves were plotted with the Kaplan-Meier method and compared with the log-rank test. The R software (version 3.3.1; R Foundation for Statistical Computing, Vienna, Austria) was used for Kaplan-Meier analysis, whereas all of the remaining calculations were performed with the SPSS statistical package (SPSS Inc., Chicago, IL, USA). Two-tailed P-values <0.05 were considered statistically significant.
RESULTS
Study patients
A flow diagram of the progress through the study is provided in Fig. 1 . Of the 505 consecutive ESCC patients who were treated with nCRT followed by surgery between January 1997 and December 2014, 123 (24.4%) patients achieved cCR. The members of our oesophageal multidisciplinary team performed a careful rereview of the clinical data of all cCR cases (blinded to the pathological results). Thirty patients were excluded, because their CT images (taken before the availability of electronic records or obtained at other institutions) were not available for re-review. In the 93 patients who had their scans re-reviewed, 10 patients had their classification changed to the non-cCR category. With regard to the remaining 83 cCR patients, we were able to retrieve the histological slides for pathological re-reviewing in 73 cases. Consequently, the final study cohort consisted of 73 ESCC who achieved cCR. Table 1 summarizes the general characteristics of cCR patients who were included or excluded in the study. No significant inter-group differences were identified. Among the 73 patients with cCR, 46 (63%) patients were found to have residual cancer (i.e. no-pCR). Table 2 summarizes the general characteristics of the cCR/pCR and cCR/no-pCR groups. No significant intergroup differences were evident both before and after nCRT. The results of univariable logistic regression analysis are summarized in Supplementary Material, Table S1 . We did not identify any significant association between pre-nCRT parameters and the occurrence of pCR in the cCR group. 
Concordance between positron emission tomography findings and final pathology results
There were 27 cCR patients who received PET before surgery. The agreement between PET findings and the final pathological diagnosis was poor (kappa statistic = 0.02; 95% confidence interval = -0.323 to 0.400). Fifteen (55.5%) patients had concordant findings between PET imaging and the final pathology, whereas they were discordant in 12 cases (44.5%; P = 0.39, McNemar's test). Detailed data of these 27 patients are shown in Fig. 2 .
Location of residual cancer in clinical complete response/no-pathological complete response patients and prevalence of cancer involvement in each oesophageal layer
The majority of patients (89.1%; n = 41) had still evidence of residual cancer in the oesophagus, whereas only 5 (10.9%) patients had T0N+ disease. The sub-mucosal layer showed the highest frequency (69.6%, n = 32) of residual cancer, followed by the mucosa (60.9%, n = 28), the muscle layer (52.2%, n = 24), the adventitia (30.4%, n = 14) and regional nodes (30.4%, n = 14). Figure 3 shows the anatomical localizations of residual cancers in cCR/nopCR patients further stratified according to the presence or the absence of mucosal involvement. Notably, a high percentage (39.1%; n = 16) of patients had no detectable cancer in the mucosa layer; of them, 9 patients did not also have any detectable cancer in the sub-mucosal layer. This observation suggests that the detection of such lesions via an endoscopic biopsy may be difficult. Table 3 summarizes the general characteristics of cCR patients who did not achieve pCR according to the presence or the absence of mucosal involvement. We failed to identify significant predictors of non-mucosal involvement in this patient group.
Survival analysis
There were 4 patients who were lost to follow-up (between 2632 and 5415 days after surgery). After a mean follow-up time of 41.6 months, 48 patients were dead (40 patients of cancerrelated causes and 8 from other causes). The 5-year OS rate in the entire study cohort was 28.8% [median survival time (MST): 26 months]. Patients who achieved pCR (5-year OS rate: 59.5%, MST: not available) had a significantly better OS than those who did not (5-year OS rate: 9%, MST: 20 months; Fig. 4 , P < 0.001). We also observed a stepwise decrease in 5-year OS rates with increasing TRG as follows: 51% (MST: 128 months) for patients with a TRG of 1, 28% (MST: 23.1 months) for patients with a TRG of 2 and 0% (MST: 9.5 months) for patients with a TRG of 3 (P < 0.001; Supplementary Material, Fig. S1 ).
In the cCR/no-pCR group, no significant differences in survival were evident according to the presence (MST: 19.2 months) or the absence of mucosal involvement (MST: 21.7 months; Fig. 5 , P = 0.5).
DISCUSSION
Recent advances in nCRT has led to significant improvements in pCR rates of patients with oesophageal cancer [3] . In this scenario, the potential feasibility of replacing the scheduled oesophagectomy with a 'close endoscopic surveillance and surgery as needed' policy has been advocated for cases without clinical evidence of disease following nCRT [4] . However, we believe that this strategy should be implemented cautiously. Our study shows that nearly 40% of the cCR/no-pCR patients had residual malignancies hidden underneath a cancer-free mucosa. In this patient group, the identification of a residual cancer may be difficult even with an active endoscopic surveillance. Among the 18 patients with residual disease not involving the mucosa, 9 patients had residual cancer in the sub-mucosal layer. Theoretically, lesions located in this layer can be initially identified through EUS and subsequently sampled via EUS-guided aspiration, direct deep biopsy (i.e. 'bite-on-bite' approach) or endoscopic sub-mucosal dissection [15] [16] [17] [18] . The reported diagnostic rate of these approaches ranges between 17% and 65.1% [15] [16] [17] [18] . In addition, EUS can be useful to detect nodal disease. However, it should be noted that such a high diagnostic rate has been reported in patients with sub-mucosal tumours (frequently presenting as endoluminal bulging masses). In contrast, the diagnostic distinction between the presence of a residual tumour versus the occurrence of post-treatment inflammatory changes may be challenging in patients who had undergone nCRT. Moreover, targeted tissue sampling in nCRT-treated cases can be problematic, ultimately reducing the likelihood of diagnostic success [19] . In this context, better tools for identifying residual malignancies are urgently needed. Unfortunately, PET and CT alone do not seem to be clinically useful to achieve this goal [20, 21] . Diffusionweighted magnetic resonance imaging holds promise for the detection of pCR, but pilot results require confirmation in larger sample sizes [22] .
Limitations
Some caveats of the current study merit comment. First, our research is limited by both its retrospective nature and a prolonged enrolment period. Despite a careful re-review of all pathological specimens, we cannot rule out the existence of differences between pathologists in the modality by which tumour specimens were processed. Second, our nCRT protocol was based on radiation doses that were lower than those currently in use (30-45 Gy vs 45-50.4 Gy). We cannot exclude that this methodological difference could have influenced the observed response patterns (characterized by a relatively low cCR rate in our study). Third, we acknowledge the relatively small sample size of our study and the corresponding low statistical power. Fourth, the diagnosis of cCR was based on the combination of CT imaging and endoscopic findings only (without EUS and PET), potentially resulting in some misclassifications. Fifth, it should be noted that approximately 20% patients who achieved cCR after nCRT did not proceed to surgical resection and could not be analysed, which might result in some selection bias. Finally, all of the study participants had a diagnosis of ESCC; consequently, our data might not be applicable to patients with oesophageal adenocarcinoma. Before definite recommendations can be given, our findings need to be independently replicated and validated in larger samples and different populations.
CONCLUSION
Nearly 40% of patients with ESCC who attained cCR but showed a pathological non-complete response had residual cancer hidden underneath a cancer-free mucosa layer.
SUPPLEMENTARY MATERIAL
Supplementary material is available at EJCTS online. 
